(2'S)-1-phenyl-3-(2'-N-tert-butoxycarbonylpyrrolidinyl)pyrazole | 217805-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2'S)-1-phenyl-3-(2'-N-tert-butoxycarbonylpyrrolidinyl)pyrazole
• 英文别名: (S)-2-(1-Phenyl-1H-pyrazol-3-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl (2S)-2-(1-phenylpyrazol-3-yl)pyrrolidine-1-carboxylate
• CAS: 217805-58-8
• 化学式: C₁₈H₂₃N₃O₂
• 分子量: 313.4
• InChiKey: HUOTVLRSJUHFTD-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2'S)-1-phenyl-3-(2'-N-tert-butoxycarbonylpyrrolidinyl)pyrazole 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (2'S)-1-phenyl-3-(2'-pyrrolidinyl)pyrazole
  参考文献：
  名称：

  The design of potent and selective inhibitors of DPP-4: Optimization of ADME properties by amide replacements

  摘要：

  For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.078
• 作为产物：
  描述：

  N-(叔丁氧基羰基)-L-脯氨酸-N′-甲氧基-N′-甲酰胺 在 sodium carbonate 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 32.0h， 生成 (2'S)-1-phenyl-3-(2'-N-tert-butoxycarbonylpyrrolidinyl)pyrazole
  参考文献：
  名称：

  Synthesis of chiral pyrazoles and isoxazoles as constrained amino acids

  摘要：

  A stereospecific syntheses of optically active pyrazoles and isoxazoles from L-proline is described. The procedure presented is based on readily available materials and can be used for preparing new conformationally restricted pyrazole-containing amino acids, (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00305-x

文献信息

• Dpp-IV Inhibitors
  申请人：Edwards John Paul

  公开号：US20080015146A1

  公开（公告）日：2008-01-17

  The invention relates to compounds of formula (I) wherein Z, R 1-9 , n, A, X and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及公式(I)的化合物，其中Z、R1-9、n、A、X和Rb的含义如所述描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这些化合物的方法，以及作为药物的生产和使用。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：SANTHERA PHARMACEUTICALS DEUTS

  公开号：WO2005121131A1

  公开（公告）日：2005-12-22

  The invention relates to compounds of formula (I); wherein Z, R1-9, n, A, X and Rb have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.
• Synthesis of chiral pyrazoles and isoxazoles as constrained amino acids
  作者：Massimo Falorni、Giampaolo Giacomelli、Anton Mario Spanedda

  DOI：10.1016/s0957-4166(98)00305-x

  日期：1998.9

  A stereospecific syntheses of optically active pyrazoles and isoxazoles from L-proline is described. The procedure presented is based on readily available materials and can be used for preparing new conformationally restricted pyrazole-containing amino acids, (C) 1998 Elsevier Science Ltd. All rights reserved.
• The design of potent and selective inhibitors of DPP-4: Optimization of ADME properties by amide replacements
  作者：Sonja Nordhoff、Stephan Bulat、Silvia Cerezo-Gálvez、Oliver Hill、Barbara Hoffmann-Enger、Meritxell López-Canet、Claudia Rosenbaum、Christian Rummey、Meinolf Thiemann、Victor G. Matassa、Paul J. Edwards、Achim Feurer

  DOI：10.1016/j.bmcl.2009.09.078

  日期：2009.11

  For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes. (C) 2009 Elsevier Ltd. All rights reserved.